While Experts recommend that people diagnosed with autism be offered genetic testing, including chromosomal microarray (CMA) testing and Fragile X testing, a study called the Rhode Island Consortium for Autism Research and Treatment (RI-CART) found that about 16.5% of participants reported receiving some genetic testing, and about 13.2% have been tested for Fragile X. About 4.5% received CMA testing. About 3% of RI-CART participants received both Fragile X and CMA testing. About 7.2% have received a karyotype test for chromosomal abnormalities. About 9.4% were unsure whether they had received any testing. About 21 . . .